TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04032899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
Study: NCT00803465

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Reference Product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Test product
Description: Small amount applied and evaluated over the course of two days

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.05% Cream-Test product
Description: Small amount applied and evaluated over the course of two days
Study: NCT03844763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: CTX: 50 mg Daily untill PD or major toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: RT: 8 Gy single shot day 8
Study: NCT02279758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03574168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T Cells
Description: T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
Study: NCT01184066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTS Intervention
Description: ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
Study: NCT00129987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management education
Study: NCT02684422

Intervention type: OTHER
Intervention: Intervention N/A. Observational study
Description: There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
Study: NCT03664713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Description: EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
Study: NCT01349634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodized salt
Description: salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
Study: NCT02609243

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting
Description: dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting
Description: dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting
Description: dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary consulting
Description: dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
Study: NCT02615223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Cryoablation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing-hormone releasing-hormone (LHRH) agonist
Description: luteinizing-hormone releasing-hormone (LHRH) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing-hormone releasing-hormone (LHRH) agonist
Description: luteinizing-hormone releasing-hormone (LHRH) agonist
Study: NCT04324398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: cold application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: cold application
Study: NCT03459781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training
Description: CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHE (Cancer Health Education)
Description: The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
Study: NCT03703739

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference meal 1
Description: 1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference 2
Description: 1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal A
Description: Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal B
Description: Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal C
Description: Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal D
Description: Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal E
Description: Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~\*\* composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate.
Study: NCT01574599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy- Repetitive Facilitative Exercise
Description: Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
Study: NCT04597554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Cranberry beverage and gummies supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo beverages and gummies supplement
Study: NCT04021901

Intervention type: DEVICE
Intervention: balloon dilatation
Description: The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)

Intervention type: DEVICE
Intervention: balloon dilatation
Description: The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)
Study: NCT04417855

Intervention type: DIAGNOSTIC_TEST
Intervention: G-Walk
Description: Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected.

Intervention type: DIAGNOSTIC_TEST
Intervention: G-Walk
Description: Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected.
Study: NCT03102346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based cardiac rehabilitation
Description: The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
Study: NCT04735523

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran dispensing claim is used as the exposure group

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference group
Study: NCT03063437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Encapsulated fecal microbiota preparation
Description: 30 capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Encapsulated placebo
Description: 30 capsules
Study: NCT03507634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid free Anesthesia dexmedetomidine and lidocaine
Description: Opioid free anesthesia with dexmedetomidine and lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based anesthesia Fentanyl and Remifentanyl
Description: Opioid based anesthesia with Fentanyl and Remifentanyl
Study: NCT03199560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tc 99m tilmanocept
Description: lymphatic mapping agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tc 99m filtered sulfur colloid
Description: lymphatic mapping agent
Study: NCT00640757

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Methionine deficient diet
Description: Hominex with a low protein diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Methionine sufficient diet
Description: Hominex, low protein diet and methionine capsules
Study: NCT03197389

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
Study: NCT01146639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DynaCT
Description: One extra set of images with DynaCT including one extra injection of contrast medium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
Study: NCT00916669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin sodium
Description: Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin sodium
Description: Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
Study: NCT03096938

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: methylation markers screening
Description: Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: methylation markers screening
Description: Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
Study: NCT00697905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous administration on days 1, 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous following Gemcitabine infusion on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Description: Intravenous infusion on day 2 to day 5
Study: NCT01109212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bindarit
Description: dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
Study: NCT01071109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Massage
Description: Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
Study: NCT01545011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training
Study: NCT02323295

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (Surgical Arm)
Description: For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease)
Study: NCT00737087

Intervention type: DEVICE
Group type: OTHER
Intervention: Delta Xtend Reverse Total Shoulder
Description: Orthopaedic implant for total shoulder replacement